Norrlands universitetssjukhus i Umeå är ett svenskt sjukhus som drivs av Region Västerbotten. Sjukhuset är granne med Umeå universitet och har också ett nära samarbete med dess medicinska fakultet. Sjukhuset är det största i Norrland och bland de största i landet.

During the past decade, Norrlands Universitetssjukhus conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 22 clinical trials were completed, i.e. on average, 43.1% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 16 clinical trials were completed. i.e. 59.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Norrlands Universitetssjukhus" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Amgen" with 5 trials sponsored, "Bayer" with 3 trials sponsored, "Karolinska Institutet" with 3 trials sponsored and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 3 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Norrlands Universitetssjukhus" #1 collaborator was "Uppsala University Hospital" with 4 trials as a collaborator, "Karolinska University Hospital" with 3 trials as a collaborator, "The Swedish Research Council" with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator and "ClinSearch" with 2 trials as a collaborator. Other collaborators include 44 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Norrlands Universitetssjukhus" are "Pulmonary Arterial Hypertension" (4 trials), "Amyotrophic Lateral Sclerosis" (3 trials), "Prostate Cancer" (3 trials), "Atrial Fibrillation" (2 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Norrlands Universitetssjukhus" in a lesser frequency.

Most popular intervention types in "Norrlands Universitetssjukhus" are "Drug" (46 trials), "Biological" (7 trials), "Other" (7 trials), "Procedure" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Carboplatin" (3 trials), "Docetaxel" (3 trials), "Botulinum toxin type A" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Norrlands Universitetssjukhus" are 58 trials for "All" genders, 5 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Norrlands Universitetssjukhus". undefined are not yet recruiting, 24 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Norrlands Universitetssjukhus, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Norrlands Universitetssjukhus, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 10 trials that are defined as “Not Applicable".